Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

The Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on first-in-class antibody treatment Evenity (romosozumab), putting yet another obstacle in the path of a drug

Latest news

More from news
Approximately 6 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics